How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Promising Pathway Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. H.R.4408/S.1906: Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access. PRV Reauthorization.
Promising Pathway Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2024 · third_quarter · Q3
Appropriations impacting patients with rare diseases. National Institutes of Health (NIH) NCATS Appropriations.
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Lab-developed tests.
Source: Senate LDA
Rare Disease Initiatives. Telehealth. Priority Review Voucher Reauthorization. H.R.4408/S.1906: Promising Pathway Act (PPA).
Accelerating Kids’ Access to Care Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Medicare / Medicaid issues impacting patients with rare diseases. H.R.4758/S.2372: Accelerating Kids Access to Care Act. Inflation Reduction Act Implementation.
Medical Nutrition Equity Act of 2023
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Rare Disease Initiatives. Newborn Screening. Affordable Care Act (ACA) Issues and Enhancements. Step Therapy. Telehealth. Priority Review Voucher Reauthorization. H.R.6892: Medical Nutrition Equity Act of 2023.
RARE Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. Rare Pediatric Disease Priority Review Vouchers (RDP-PRV). Pediatric Study Requirements. Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access.
RARE Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Lab-developed tests.
RARE Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. H.R.4408/S.1906: Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access. PRV Reauthorization.
RARE Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. H.R.4408/S.1906: Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access. PRV Reauthorization.
RARE Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. Rare Pediatric Disease Priority Review Vouchers (RDP-PRV). Pediatric Study Requirements. Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access.
RARE Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Lab-developed tests.
Promising Pathway Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Rare Disease Initiatives. Telehealth. Priority Review Voucher Reauthorization. H.R.4408/S.1906: Promising Pathway Act (PPA).
Promising Pathway Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. H.R.4408/S.1906: Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access. PRV Reauthorization.
Accelerating Kids’ Access to Care Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Medicare / Medicaid issues impacting patients with rare diseases. H.R.4758/S.2372: Accelerating Kids Access to Care Act. Inflation Reduction Act Implementation.
RARE Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. S.1214 - RARE Act. Inflation Reduction Act Implementation.
RARE Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. S.1214: RARE Act. Inflation Reduction Act Implementation. Pediatric Review Vouchers.
Accelerating Kids’ Access to Care Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Medicare / Medicaid issues impacting patients with rare diseases. H.R.3089/S.1544: Accelerating Kids Access to Care Act. Inflation Reduction Act Implementation.
Accelerating Kids’ Access to Care Act
Client: NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) · Firm: NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
Medicare / Medicaid issues impacting patients with rare diseases. H.R.3089/S.1544: Accelerating Kids Access to Care Act. Inflation Reduction Act Implementation.
Medicare / Medicaid issues impacting patients with rare diseases. Inflation Reduction Act Implementation.
Rare Disease Initiatives. Newborn Screening. Affordable Care Act (ACA) Issues and Enhancements. Step Therapy. Telehealth. Priority Review Voucher Reauthorization. H.R.6892: Medical Nutrition Equity Act of 2023.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2024 · second_quarter · Q2
Rare Disease Initiatives. Telehealth. Priority Review Voucher Reauthorization. H.R.4408/S.1906: Promising Pathway Act (PPA).
Appropriations impacting patients with rare diseases. National Institutes of Health (NIH) NCATS Appropriations. Advanced Research Projects Agency - Health (ARPA-H) Appropriations.
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. H.R.4408/S.1906: Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access. PRV Reauthorization.
Medicare / Medicaid issues impacting patients with rare diseases. H.R.4758/S.2372: Accelerating Kids Access to Care Act. Inflation Reduction Act Implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2024 · first_quarter · Q1
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. Rare Pediatric Disease Priority Review Vouchers (RDP-PRV). Pediatric Study Requirements. Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access.
Medicare / Medicaid issues impacting patients with rare diseases. Inflation Reduction Act Implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2023 · fourth_quarter · Q4
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. S.1214: RARE Act. Inflation Reduction Act Implementation. Pediatric Review Vouchers.
Medicare / Medicaid issues impacting patients with rare diseases. Inflation Reduction Act Implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2023 · third_quarter · Q3
Medicare / Medicaid issues impacting patients with rare diseases. Inflation Reduction Act Implementation.
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. S.1214 - RARE Act. Inflation Reduction Act Implementation.
Appropriations impacting patients with rare diseases. Advanced Research Projects Agency - Health (ARPA-H) Appropriations. National Institutes of Health (NIH) NCATS Appropriations.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2023 · second_quarter · Q2
Medicare / Medicaid issues impacting patients with rare diseases. Inflation Reduction Act Implementation.
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Inflation Reduction Act Implementation.
Appropriations impacting patients with rare diseases. National Institutes of Health (NIH) NCATS Appropriations.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2023 · first_quarter · Q1
Appropriations impacting patients with rare diseases. National Institute of Health (NIH) NCATS Appropriations. Advanced Research Projects Agency-Health (ARPA-H) Appropriations.
Rare Disease Initiatives. Newborn Screening. Genetic Testing Access. Affordable Care Act (ACA) Issues and Enhancements. Telehealth.
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. Inflation Reduction Act Implementation.
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2022 · fourth_quarter · Q4
Medicare / Medicaid issues impacting patients with rare diseases. H.R.3089/S.1544: Accelerating Kids Access to Care Act. Inflation Reduction Act Implementation.
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Rare Disease Trial Design. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. Inflation Reduction Act Implementation. NIH Translation Science Issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) via NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)
2022 · third_quarter · Q3
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Rare Disease Trial Design. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. Clinical Trial Diversity. Patient-focused drug development.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Medicare / Medicaid issues impacting patients with rare diseases. Inflation Reduction Act Implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE